Categories
Disease Modifying Anti-rheumatic Drugs,DMARDs Mycophenolate Pharmacology Physiotherapy

Mycophenolate and Hepatic Insufficiency

In this article we will discuss Mycophenolate and Hepatic Insufficiency

In this article, we will discuss Mycophenolate and Hepatic Insufficiency. So, let’s get started.

Mycophenolate and Hepatic Insufficiency

In a single-dose (1 g oral) study of 18 volunteers with alcoholic cirrhosis and 6 healthy volunteers, hepatic MPA glucuronidation processes appeared to be relatively unaffected by hepatic parenchymal disease when pharmacokinetic parameters of healthy volunteers and alcoholic cirrhosis patients within this study were compared. However, it should be noted that for unexplained reasons, the healthy volunteers in this study had about a 50% lower AUC as compared to healthy volunteers in other studies, thus making comparisons
between volunteers with alcoholic cirrhosis and healthy volunteers difficult. Effects of
hepatic disease on this process probably depend on the particular disease. Hepatic disease with other etiologies, such as primary biliary cirrhosis, may show a different effect. In a single-dose (1 g intravenous) study of 6 volunteers with severe hepatic impairment
(aminopyrine breath test less than 0.2% of dose) due to alcoholic cirrhosis, MMF was
rapidly converted to MPA. MPA AUC was 44.1 μg•h/mL (±15.5).

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.